Arcus Biosciences Statistics
Share Statistics
Arcus Biosciences has 91.51M shares outstanding. The number of shares has increased by 22.14% in one year.
| Shares Outstanding | 91.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.52% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 48.15M |
| Failed to Deliver (FTD) Shares | 1.50K |
| FTD / Avg. Volume | 0.2% |
Short Selling Information
The latest short interest is 6.65M, so 7.27% of the outstanding shares have been sold short.
| Short Interest | 6.65M |
| Short % of Shares Out | 7.27% |
| Short % of Float | 13.83% |
| Short Ratio (days to cover) | 8.38 |
Valuation Ratios
The PE ratio is -4.6 and the forward PE ratio is -3.59.
| PE Ratio | -4.6 |
| Forward PE | -3.59 |
| PS Ratio | 12.08 |
| Forward PS | 7.3 |
| PB Ratio | 3.06 |
| P/FCF Ratio | -4.28 |
| PEG Ratio | n/a |
Enterprise Valuation
Arcus Biosciences Inc. has an Enterprise Value (EV) of 1.30B.
| EV / Earnings | -4.23 |
| EV / Sales | 11.09 |
| EV / EBITDA | -4.58 |
| EV / EBIT | -3.82 |
| EV / FCF | -3.93 |
Financial Position
The company has a current ratio of 4.52, with a Debt / Equity ratio of 0.
| Current Ratio | 4.52 |
| Quick Ratio | 4.52 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -170 |
Financial Efficiency
Return on equity (ROE) is -0.66% and return on capital (ROIC) is -73.31%.
| Return on Equity (ROE) | -0.66% |
| Return on Assets (ROA) | -0.28% |
| Return on Capital (ROIC) | -73.31% |
| Revenue Per Employee | 202.77K |
| Profits Per Employee | -532.06K |
| Employee Count | 577 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 6.00M |
| Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by -11.09% in the last 52 weeks. The beta is 0.89, so Arcus Biosciences 's price volatility has been higher than the market average.
| Beta | 0.89 |
| 52-Week Price Change | -11.09% |
| 50-Day Moving Average | 16.54 |
| 200-Day Moving Average | 16.32 |
| Relative Strength Index (RSI) | 56.37 |
| Average Volume (20 Days) | 739.84K |
Income Statement
In the last 12 months, Arcus Biosciences had revenue of $117.00M and earned -$307.00M in profits. Earnings per share was $-4.15.
| Revenue | 117.00M |
| Gross Profit | -223.00M |
| Operating Income | -340.00M |
| Net Income | -307.00M |
| EBITDA | -283.00M |
| EBIT | -340.00M |
| Earnings Per Share (EPS) | -4.15 |
Balance Sheet
The company has $127.00M in cash and $11.00M in debt, giving a net cash position of $116.00M.
| Cash & Cash Equivalents | 127.00M |
| Total Debt | 11.00M |
| Net Cash | 116.00M |
| Retained Earnings | -849.00M |
| Total Assets | 1.25B |
| Working Capital | 912.00M |
Cash Flow
In the last 12 months, operating cash flow was -$306.00M and capital expenditures -$24.00M, giving a free cash flow of -$330.00M.
| Operating Cash Flow | -306.00M |
| Capital Expenditures | -24.00M |
| Free Cash Flow | -330.00M |
| FCF Per Share | -4.46 |
Margins
Gross margin is -190.6%, with operating and profit margins of -290.6% and -262.39%.
| Gross Margin | -190.6% |
| Operating Margin | -290.6% |
| Pretax Margin | -257.26% |
| Profit Margin | -262.39% |
| EBITDA Margin | -241.88% |
| EBIT Margin | -290.6% |
| FCF Margin | -282.05% |
Dividends & Yields
RCUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -25.76% |
| FCF Yield | -22.38% |
Analyst Forecast
The average price target for RCUS is $30, which is 86.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $30 |
| Price Target Difference | 86.2% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 0.54 |
| Piotroski F-Score | 4 |